순환종양세포(CTC) 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 용도별, 검체별, 제품별, 기술별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Circulating Tumor Cells Market Size, Share & Trends Analysis Report By Application (Clinical, Research), By Specimen (Bone Marrow, Blood), By Product, By Technology, By End Use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,404,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,816,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,641,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

순환종양세포(CTC) 시장의 성장 및 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 순환종양세포(CTC) 시장 규모는 2025-2030년 연평균 복합 성장률(CAGR) 12.2%로 확대될 전망이며, 2030년에는 249억 6,000만 달러에 이를 것으로 추정됩니다.

이 배경에는 세계의 암 유병률 상승, 비침습적 암 진단 도구에 대한 수요 증가, 순환종양세포(CTC) 기술의 진보가 있습니다.

최근 CTC는 암 예후를 결정하고 임상의가 암 치료에 필요한 치료법의 유형을 결정하기 위해 점점 사용되고 있습니다. CTC는 암의 조기 발견, 암 재발 위험 평가, 치료 지침, 암 치료 중인 환자의 지속적인 모니터링 등 암 관리의 다양한 분야에서 폭넓게 응용되고 있습니다. 암 진단 및 모니터링에 사용할 수 있는 CTC를 이용한 다양한 종양 표지자 개발은 예측 기간 동안 CTC의 채택을 촉진할 것으로 예상됩니다. 따라서 암 환자의 말초혈에서 CTC 검출은 유망한 진단 도구로 기능한다고 결론지을 수 있습니다. 예를 들어 CTC의 정량화와 유전체 프로파일링은 전립선암의 비용 대비 효과가 높고 정확한 비침습적 모니터링을 가능하게 합니다. CTC의 검출은 암 환자의 생존을 예측합니다.

희소암에서는 이러한 세포의 적용범위가 한정되어 있기 때문에 수익의 성장은 어느 정도 방해되고 있습니다. 순환종양세포(CTC)는 신경원성암과 같은 EpCAM 음성 또는 저발현을 특징으로 하는 종양에는 적용되지 않습니다. 예를 들어 육종에 대한 순환종양세포(CTC)의 특징을 나타내는 증거는 거의 없습니다. 반대로, 상피 항원을 표적으로 한 항체를 이용한 방법 등, 이러한 세포를 분리하기 위한 많은 방법이 연구되고 있어, 가까운 장래에 이러한 과제가 극복될 것으로 기대되고 있습니다.

그러나 최근 밸류체인의 형성과 CTC 시장의 성장을 가속시키기 위해 대기업에 의한 인수 및 제약기업과의 수많은 제휴에 의한 기술의 일원화가 잇따라 실용화가 추진되고 있습니다. 예를 들어 워싱턴대 의대는 2023년 6월 전이암이 혈액 속으로 배출하는 종양세포를 검출하는 신규 검사법을 개발하기 위해 시애틀에 본사를 둔 바이오테크놀로지 기업 RareCyte사와 손을 잡았습니다. 또한 조사에 따르면 혈류 속 순환종양세포(CTC)를 파악함으로써 종양세포의 변화를 추적할 수 있어 치료의 최적화가 가능해진다고 합니다.

순환종양세포(CTC) 시장 보고서 하이라이트

• 기술별로는 CTC 농축 및 분리를 위한 제품 이용 가능성 증가, 세계의 높은 이용률 및 제품 침투로 CTC 검출 및 농축법 분야가 2024년 40.92%의 최대 매출 점유율을 차지했습니다.
• CTC 분석은 연구 연구, 의약품 개발, 바이오마커 연구에 대한 용도 가능성이 높아지고 있기 때문에 예측 기간 중에 가장 빠른 CAGR을 기록할 전망입니다.
• 용도별로는 조사 부문이 2024년 시장을 독점하였으며, 2025-2030년 가장 빠른 CAGR을 나타낼 것으로 예측되고 있습니다.
• 제품별로는 키트 및 시약이 2024년에 시장을 석권했고, 2025-2030년 예측 기간 가장 빠른 성장이 전망되고 있습니다.
• 검체별로는 혈액 부문이 2024년에 시장을 석권했습니다. 기타 체액 부문은 2025-2030년 가장 빠른 CAGR이 전망됩니다.
• 최종 용도별로는 암 진단 및 치료를 위한 연구 개발 활동에 대한 주목이 높아지고 있는 것으로부터, 연구 및 학술 기관 부문(segment)가 2024년 시장을 독점했습니다.
• 북미가 2024년에 CTC 시장을 독점한 것은 주요 시장 기업인 Bio-Techne Corporation, Precision Medicine Group LLC, Epic Sciences, APPLIED DNA SCIENCES, INC., LungLife AI, Inc.의 존재와 이 지역 내 제약 및 바이오 테크놀로지 연구 부문의 성장 등의 요인에 의한 것입니다.
• 아시아태평양은 일본과 같은 나라에서 프레즌스를 확대하고 있는 여러 기업에 의해 예측 기간 중에 가장 빠른 CAGR을 나타낼 것으로 예상되고 있습니다.

목차

제1장 조사 방법 및 범위

제2장 주요 요약

제3장 순환종양세포(CTC) 시장의 변수, 동향 및 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련 및 부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 순환종양세포(CTC) 시장 분석 도구
  • 업계 분석-Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 순환종양세포(CTC) 시장 : 기술별 추정 및 동향 분석

• 기술별 부문 대시보드
• 세계의 순환종양세포(CTC) 시장 기술별 변동 분석
• 세계의 순환종양세포(CTC) 시장 규모 및 동향 분석 : 기술별(2018-2030년)
• 시장 규모와 예측 및 동향 분석(2018-2030년)
  • CTC 검출 및 농축법
  • CTC 직접 검출법
  • CTC 분석

제5장 순환종양세포(CTC) 시장 : 용도별 추정 및 동향 분석

• 용도별 부문 대시보드
• 세계의 순환종양세포(CTC) 시장 용도별 변동 분석
• 세계의 순환종양세포(CTC) 시장 규모 및 동향 분석 : 용도별(2018-2030년)
• 시장 규모와 예측 및 동향 분석(2018-2030년)
  • 임상
  • 조사

제6장 순환종양세포(CTC) 시장 : 제품별 추정 및 동향 분석

• 제품별 부문 대시보드
• 세계의 순환종양세포(CTC) 시장 제품별 변동 분석
• 세계의 순환종양세포(CTC) 시장 규모 및 동향 분석 : 제품별(2018-2030년)
• 시장 규모와 예측 및 동향 분석(2018-2030년)
  • 키트 및 시약
  • 채혈관
  • 디바이스 또는 시스템

제7장 순환종양세포(CTC) 시장 : 검체별 추정 및 동향 분석

• 검체별 부문 대시보드
• 세계의 순환종양세포(CTC) 시장 검체별 변동 분석
• 세계의 순환종양세포(CTC) 시장 규모 및 동향 분석 : 검체별(2018-2030년)
• 시장 규모와 예측 및 동향 분석(2018-2030년)
  • 피
  • 골수
  • 기타 체액

제8장 순환종양세포(CTC) 시장 : 최종 용도별 추정 및 동향 분석

• 최종 용도별 부문 대시보드
• 세계의 순환종양세포(CTC) 시장 최종 용도별 변동 분석
• 세계의 순환종양세포(CTC) 시장 규모 및 동향 분석 : 최종 용도별(2018-2030년)
• 시장 규모와 예측 및 동향 분석(2018-2030년)
  • 조사 및 학술 기관
  • 병원 및 진료소
  • 진단센터

제9장 순환종양세포(CTC) 시장 : 지역별 추정 및 동향 분석

• 지역별 시장 점유율 분석(2024년, 2030년)
• 지역별 시장 대시보드
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제10장 경쟁 구도

• 주요 시장 진출 기업에 의한 최근의 동향 및 영향 분석
• 기업 및 경쟁의 분류
• 벤더 상황
  • 주요 리셀러 및 채널 파트너 목록
  • 주요 고객
  • 주요 기업의 포지션 분석(2024년)
  • QIAGEN
  • Bio-Techne Corp.
  • Precision Medicine Group, LLC.
  • Bio-Rad Laboratories, Inc.
  • Natera, Inc.
  • Illumina, Inc.
  • Cell Microsystems
  • Greiner Bio One International GmbH
  • Ikonisys Inc.
  • Miltenyi Biotec
  • Creative Bioarray
  • BioFluidica
  • Abnova Corporation
  • Biolidics Limited
  • Creativ MicroTech, Inc.
  • LungLife AI
  • Epic Sciences
  • Rarecells Diagnostics
  • ScreenCell
  • Menarini Silicon Biosystems
  • APPLIED DNA SCIENCES, INC.
  • Sysmex Corporation
  • STEMCELL Technologies, Inc.

AJY

영문 목차

영문목차

Circulating Tumor Cells Market Growth & Trends:

The global circulating tumor cells market size is estimated to reach USD 24.96 billion by 2030, expanding at a CAGR of 12.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. This is attributed to rising prevalence of cancer worldwide, increasing demand for non-invasive cancer diagnostic tools, and advancements in circulating tumor cells (CTC) technologies.

In recent years, CTCs are increasingly used for determining the prognosis of cancer and helping clinicians decide the type of therapy required for cancer treatment. CTCs have wide applications in several areas of cancer management-early detection of cancer, risk assessment of cancer recurrence, guidance for therapies, and continuous monitoring of a patient during cancer treatment. The development of various tumor markers utilizing CTCs, which can be used to diagnose or monitor cancer, is expected to boost the adoption of CTCs over the forecast period. Therefore, it can be concluded that the detection of CTCs in the peripheral blood of patients with cancer acts as a promising diagnostic tool. For instance, quantitation and genomic profiling of CTCs enables cost-effective & accurate noninvasive monitoring of prostate cancer. The detection of CTCs is predictive for survival of cancer patients.

The limited applicability of these cells in rare cancers has hampered revenue growth to a certain extent. Circulating tumor cells are not applicable to tumors characterized by EpCAM negativity or low expression, such as neurogenic cancers. For instance, there is negligible evidence for the characterization of circulating tumor cells for sarcoma. Conversely, numerous methods are being studied for the isolation of these cells, which include methods based on epithelial antigen-targeted antibodies, anticipating to overcome these challenges in the near future.

However, in recent years, there has been a push for practical application, largely as a result of a wave of large players centralizing the technology through acquisitions and numerous partnerships with pharmaceutical firms to advance the formation of a value chain and speed up the CTC market's growth. For instance, in June 2023, to develop a novel test for the detection of tumor cells that metastatic cancers shed into the blood, the University of Washington School of Medicine collaborated with RareCyte, Inc., which is a biotech company headquartered in Seattle. In addition, according to the research, the understanding of the circulating tumor cells in the bloodstream can track the changes in tumor cells, thus optimizing the treatment.

Circulating Tumor Cells Market Report Highlights:

• Based on technology, The CTC detection and enrichment methods segment accounted for the largest revenue share of 40.92% in 2024 owing to the increased availability of products for CTC enrichment and isolation as well as high usage and product penetration across the globe
• CTC analysis is expected to register the fastest CAGR during the forecast period due to the growing application potential of CTC analysis for investigational research, drug development, and biomarker studies
• Based on application, the research segment dominated the market in 2024 and it is expected to witness the fastest CAGR from 2025 to 2030
• Kits & reagent dominated the product segment in 2024, and it is expected to witness the fastest growth in forecast period of 2025-2030
• Based on specimen, the blood segment dominated the market in 2024. The other body fluids segment is expected to witness the fastest CAGR from 2025 to 2030
• Based on end-use, the research & academic institutes segment dominated the market in 2024 due to increasing focus on research and development activities for cancer diagnosis and treatment
• North America dominated the CTC market in 2024, owing to factors such as the presence of key market players Bio-Techne Corporation, Precision Medicine Group LLC, Epic Sciences, APPLIED DNA SCIENCES, INC., and LungLife AI, Inc. and the growth in pharmaceutical & biotechnology research sectors in this region
• Asia Pacific is expected to register the fastest CAGR over the forecast period due to several companies expanding their presence in countries like Japan

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology
  • 1.2.2. Application
  • 1.2.3. Product
  • 1.2.4. Specimen
  • 1.2.5. End use
• 1.3. Research Methodology
• 1.4. Information Procurement
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Circulating Tumor Cells Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Advancements in chip technology
    • 3.2.1.2. Expanding applications of CTCs
    • 3.2.1.3. Growing demand for early and rapid cancer diagnosis
    • 3.2.1.4. Growing incidence of cancer
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Consistency-related challenges in CTC detection and enrichment
    • 3.2.2.2. Higher preference for Point-of-Care (POC) testing and nonavailability of POC adaptable CTC tests
    • 3.2.2.3. Lower applicability of CTCs in rare cancers
• 3.3. Circulating Tumor Cells Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Circulating Tumor Cells Market: Technology Estimates & Trend Analysis

• 4.1. Technology Segment Dashboard
• 4.2. Global Circulating Tumor Cells Market Technology Movement Analysis
• 4.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. CTC Detection & Enrichment Methods
    • 4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.1.2. Immunocapture (Label-based)
      • 4.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.1.2.2. Positive Selection
        • 4.4.1.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.1.2.3. Negative Selection
        • 4.4.1.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.1.3. Size-based Separation (Label-free)
      • 4.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.1.3.2. Membrane-based
        • 4.4.1.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.1.3.3. Microfluidic-based
        • 4.4.1.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.1.4. Density-based Separation (Label-free)
      • 4.4.1.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.1.5. Combined Methods
      • 4.4.1.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.2. CTC Direct Detection Methods
    • 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.2.2. SERS
      • 4.4.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.2.3. Microscopy
      • 4.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.2.4. Others
      • 4.4.2.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.3. CTC Analysis
    • 4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Circulating Tumor Cells Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global Circulating Tumor Cells Market Application Movement Analysis
• 5.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Clinical
    • 5.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.1.2. Risk Assessment
      • 5.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.1.3. Screening and Monitoring
      • 5.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4.2. Research
    • 5.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.2.2. Cancer Stem Cell & Tumorogenesis Research
      • 5.4.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.2.3. Drug/Therapy Development
      • 5.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Circulating Tumor Cells Market: Product Estimates & Trend Analysis

• 6.1. Product Segment Dashboard
• 6.2. Global Circulating Tumor Cells Market Product Movement Analysis
• 6.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Kits & reagents
    • 6.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
  • 6.4.2. Blood collection tubes
    • 6.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.3. Devices or systems
    • 6.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Circulating Tumor Cells Market: Specimen Estimates & Trend Analysis

• 7.1. Specimen Segment Dashboard
• 7.2. Global Circulating Tumor Cells Market Specimen Movement Analysis
• 7.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Specimen, 2018 to 2030 (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Blood
    • 7.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
  • 7.4.2. Bone marrow
    • 7.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.3. Other body fluids
    • 7.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Circulating Tumor Cells Market: End Use Estimates & Trend Analysis

• 8.1. End Use Segment Dashboard
• 8.2. Global Circulating Tumor Cells Market End Use Movement Analysis
• 8.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.4.1. Research and academic institutes
    • 8.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
  • 8.4.2. Hospital and clinics
    • 8.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.4.3. Diagnostic centers
    • 8.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 9. Circulating Tumor Cells Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key country dynamics
    • 9.3.1.2. Regulatory framework
    • 9.3.1.3. Competitive scenario
    • 9.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.3.1.5. Target disease prevalence
  • 9.3.2. Canada
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.3.2.5. Target disease prevalence
  • 9.3.3. Mexico
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.3.3.5. Target disease prevalence
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework
    • 9.4.1.3. Competitive scenario
    • 9.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.1.5. Target disease prevalence
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.2.5. Target disease prevalence
  • 9.4.3. France
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.3.5. Target disease prevalence
  • 9.4.4. Italy
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.4.5. Target disease prevalence
  • 9.4.5. Spain
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.5.5. Target disease prevalence
  • 9.4.6. Norway
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.6.5. Target disease prevalence
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.7.5. Target disease prevalence
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Regulatory framework
    • 9.4.8.3. Competitive scenario
    • 9.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.8.5. Target disease prevalence
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.1.5. Target disease prevalence
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.2.5. Target disease prevalence
  • 9.5.3. India
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.3.5. Target disease prevalence
  • 9.5.4. Australia
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.4.5. Target disease prevalence
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.5.5. Target disease prevalence
  • 9.5.6. Thailand
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.6.5. Target disease prevalence
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.6.1.5. Target disease prevalence
  • 9.6.2. Argentina
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.6.2.5. Target disease prevalence
• 9.7. MEA
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.7.1.5. Target disease prevalence
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.7.2.5. Target disease prevalence
  • 9.7.3. UAE
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.7.3.5. Target disease prevalence
  • 9.7.4. Kuwait
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.7.4.5. Target disease prevalence

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Key company position analysis, 2024
  • 10.3.4. QIAGEN
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Product benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Bio-Techne Corp.
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Product benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Precision Medicine Group, LLC.
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Product benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Bio-Rad Laboratories, Inc.
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Product benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Natera, Inc.
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Product benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Illumina, Inc.
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Product benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. Cell Microsystems
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Product benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. Greiner Bio One International GmbH
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Product benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Ikonisys Inc.
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Product benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. Miltenyi Biotec
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Product benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. Creative Bioarray
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Product benchmarking
    • 10.3.14.4. Strategic initiatives
  • 10.3.15. BioFluidica
    • 10.3.15.1. Company overview
    • 10.3.15.2. Financial performance
    • 10.3.15.3. Product benchmarking
    • 10.3.15.4. Strategic initiatives
  • 10.3.16. Abnova Corporation
    • 10.3.16.1. Company overview
    • 10.3.16.2. Financial performance
    • 10.3.16.3. Product benchmarking
    • 10.3.16.4. Strategic initiatives
  • 10.3.17. Biolidics Limited
    • 10.3.17.1. Company overview
    • 10.3.17.2. Financial performance
    • 10.3.17.3. Product benchmarking
    • 10.3.17.4. Strategic initiatives
  • 10.3.18. Creativ MicroTech, Inc.
    • 10.3.18.1. Company overview
    • 10.3.18.2. Financial performance
    • 10.3.18.3. Product benchmarking
    • 10.3.18.4. Strategic initiatives
  • 10.3.19. LungLife AI
    • 10.3.19.1. Company overview
    • 10.3.19.2. Financial performance
    • 10.3.19.3. Product benchmarking
    • 10.3.19.4. Strategic initiatives
  • 10.3.20. Epic Sciences
    • 10.3.20.1. Company overview
    • 10.3.20.2. Financial performance
    • 10.3.20.3. Product benchmarking
    • 10.3.20.4. Strategic initiatives
  • 10.3.21. Rarecells Diagnostics
    • 10.3.21.1. Company overview
    • 10.3.21.2. Financial performance
    • 10.3.21.3. Product benchmarking
    • 10.3.21.4. Strategic initiatives
  • 10.3.22. ScreenCell
    • 10.3.22.1. Company overview
    • 10.3.22.2. Financial performance
    • 10.3.22.3. Product benchmarking
    • 10.3.22.4. Strategic initiatives
  • 10.3.23. Menarini Silicon Biosystems
    • 10.3.23.1. Company overview
    • 10.3.23.2. Financial performance
    • 10.3.23.3. Product benchmarking
    • 10.3.23.4. Strategic initiatives
  • 10.3.24. APPLIED DNA SCIENCES, INC.
    • 10.3.24.1. Company overview
    • 10.3.24.2. Financial performance
    • 10.3.24.3. Product benchmarking
    • 10.3.24.4. Strategic initiatives
  • 10.3.25. Sysmex Corporation
    • 10.3.25.1. Company overview
    • 10.3.25.2. Financial performance
    • 10.3.25.3. Product benchmarking
    • 10.3.25.4. Strategic initiatives
  • 10.3.26. STEMCELL Technologies, Inc.
    • 10.3.26.1. Company overview
    • 10.3.26.2. Financial performance
    • 10.3.26.3. Product benchmarking
    • 10.3.26.4. Strategic initiatives

관련자료